What Is the First-Line Treatment of Influenza?
Influenza is an acute respiratory illness in which the timing of antiviral treatment is critical. Evidence consistently shows that the sooner therapy is started after symptom onset, the better the clinical outcome.
Treatment Approach
The recommended approach centres on early initiation of a single agent from the neuraminidase inhibitor (NAI) class of antivirals. Importantly, only one NAI should be used at a time — combining agents from this class is not supported by evidence and is not recommended. Several options within this class are available, and the selection and full regimen details are covered in the structured protocol.
Clinical Goals
The primary objective is reduction in the duration of fever and influenza symptoms. Early antiviral initiation — particularly within the first two days of illness onset — is associated with the greatest symptomatic benefit.
References
DOI: 10.1093/cid/ciy866
- Clinicians should start antiviral treatment as soon as possible with a single neuraminidase inhibitor (NAI) (either oral oseltamivir, inhaled zanamivir, or intravenous peramivir) and not use a combination of NAIs (A-1).
- Clinicians should treat uncomplicated influenza in otherwise healthy ambulatory patients for 5 days with oral oseltamivir or inhaled zanamivir, or a single dose of intravenous peramivir (A-1).
- Systematic reviews and meta-analyses of RCTs indicate that early initiation (within 2 days of illness onset) of antiviral treatment can reduce the duration of fever and symptoms, especially in nonasthmatic children; decrease the risk of otitis media in children; and reduce the risk of lower respiratory tract complications requiring antibiotics and of hospitalization in adults.
View source ↗